RE:RE:Average cost to bring drug candidate to market = US$2.3 Bln Pelareorep's ability to "prime" the innate and adaptive immune system has been documented and pelareorep's PFS is about to be elaberated in a major medical meeting in the next 3 months, according to ONCY in repeated corporate updates.
And any reference to a 400 patient Phase III clinical trial also may also be referencing a Phase 3/4 confirmatory trial AFTER an accelerated approval has been granted in metastatic breast cancer (mBC). And another trial to consider is a trial in triple negative breast cancer (TNBC) which is a completely different indication than mBC.